Pfizer’s revenue estimates
Analysts expect a 0.5% fall in Pfizer’s (PFE) 2Q17 revenues to $13.08 billion, following a decline in revenues from blockbuster drugs including Celebrex, Zyvox, and Lyrica, partially offset by the increased sales of the Prevnar family of drugs, Xalkori, Xeljanz, and legacy Hospira products.
Segment-wise expectations 2Q17
Pfizer’s product portfolio is segregated into two business segments: Innovative Health and Essential Health.
Pfizer’s Innovative Health business was previously referred as the Innovative Pharmaceuticals business and includes the global innovative pharmaceuticals, global vaccines, oncology, and consumer healthcare. The segment contributes ~50% of Pfizer’s total revenues and is expected to report growth in 2Q17 due to the strong performance of Eliquis, Ibrance, Lyrica, Xeljanz, and Xtandi. The company’s alliance revenues are expected to contribute to the growth of its innovative health business.
The Essential Health segment
Pfizer’s Essential Health business was previously referred to as the established pharmaceuticals business and includes established products as well as legacy Hospira products. Excluding the legacy Hospira products, the established pharmaceuticals products are losing revenues due to increased competition across all major markets.
This segment includes Celebrex, Zyvox, and Lyrica, which are all losing revenues to generic competition. Revenues from this segment (including those from Hospira products) are expected to fall in 2Q17.
Foreign exchange is also expected to impact Pfizer’s overall revenues in 2Q17.
To divest company-specific risks, investors can consider ETFs like the Vanguard Health Care ETF (VHT), which has 5.5% of its total assets in Pfizer. VHT also has 10.0% in Johnson & Johnson (JNJ), 2.3% in Eli Lilly (LLY), and 3.2% in AbbVie (ABBV).
ExxonMobil (XOM) posted its 2Q17 results on July 28. XOM’s 2Q17 revenues surpassed Wall Street estimates by 2%.
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.